Aethlon Medical Jumps on North Immunology Merger and $180 Million Financing Plan

By: Quiver PriceTracker

Posted: 3 weeks ago / Sept. 17, 2026 2:49 p.m. UTC

AEMD

Aethlon Medical (AEMD) is up 400.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is Aethlon Medical’s Sept. 17 announcement of a definitive all-stock merger with private biotech North Immunology. The deal adds a much larger development story, a planned cash infusion, and a new public-market identity, while AEMD’s very small post-split share count likely helped intensify the move.

Details:

Aethlon said it signed a definitive merger agreement with North Immunology, which is developing NOR-101, a bispecific antibody candidate for atopic dermatitis and other immune-mediated diseases.

The transaction includes an oversubscribed private placement expected to bring in about $180 million in gross proceeds, with the combined company’s operations projected to be funded into the second half of 2028.

After closing, the combined business is expected to operate as North Immunology and trade on Nasdaq under the new ticker NRTX, giving investors exposure to a different pipeline than Aethlon’s legacy business.

Aethlon said its pre-merger stockholders are expected to own about 4.75% of the combined company and also receive contingent value rights tied to potential monetization of the legacy Hemopurifier business. A prior reverse split reduced outstanding shares to roughly 649,914, which could have made the rally more volatile.

Sources:

Aethlon Medical, SEC, Nasdaq Trader

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$AEMD Hedge Fund Activity

We have seen 11 institutional investors add shares of $AEMD stock to their portfolio, and 5 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANE STREET GROUP, LLC added 38,880 shares (+inf%) to their portfolio in Q2 2026, for an estimated $160,068
SHAY CAPITAL LLC added 16,948 shares (+120.0%) to their portfolio in Q2 2026, for an estimated $69,774
HRT FINANCIAL LP added 14,549 shares (+inf%) to their portfolio in Q2 2026, for an estimated $59,898
IKARIAN CAPITAL, LLC added 11,491 shares (+400.0%) to their portfolio in Q2 2026, for an estimated $47,308
SCIENTECH RESEARCH LLC added 10,054 shares (+inf%) to their portfolio in Q2 2026, for an estimated $41,392
VIRTU FINANCIAL LLC added 5,563 shares (+inf%) to their portfolio in Q2 2026, for an estimated $22,902
XTX TOPCO LTD removed 2,668 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $10,984

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.